Skip to main content

G-Spot Amplification ("G-Shot")

G-spot amplification (the "G-shot") is a cosmetic procedure that injects a dermal filler (typically hyaluronic acid), collagen or autologous fat into the anterior vaginal wall at the putative Gräfenberg spot, with the goal of enhancing sexual pleasure and orgasm. It is among the most controversial female genital cosmetic procedures. The anatomical existence of the G-spot as a discrete structure is disputed, and no randomized trial of G-spot amplification itself is known. ACOG 2020 holds that procedures to alter sexual appearance or function, other than those done for clinical indications, are not medically indicated and that their safety and effectiveness have not been established. FIGO 2025 holds that it is ethically inappropriate for obstetrician-gynecologists to recommend, perform or refer women without structural or functional abnormalities for cosmetic genital procedures.[1][2][3] For positioning versus other female cosmetic options see Cosmetic Genital Surgery — Female.

Society positioning and anatomic-existence caveat.

  • Anatomy. A literature review concluded that "all published scientific data point to the fact that the G-spot does not exist" as a distinct anatomical entity. The review also concluded that G-spot amplification is not medically indicated.[1]
  • ACOG 2020 Committee Opinion No. 795. Cosmetic genital procedures, including G-spot amplification, are not medically indicated, pose substantial risk, and have not had their safety and effectiveness established. For G-spot amplification, as for laser assistance and rugation restoration, published data are mostly restricted to expert opinion, case reports and small case series.[2]
  • FIGO 2025 Statement. It is ethically inappropriate for obstetrician-gynecologists to recommend, perform, or refer patients for cosmetic genital procedures in women without structural or functional abnormalities.[3]
  • Psychological assessment. Assess for body dysmorphic disorder when indicated; refer patients with suspected psychological concerns for evaluation before considering a procedure.[2]

Background — the G-spot controversy​

In 1950, Ernst Gräfenberg described a distinct erotogenic zone on the anterior vaginal wall. The term "G-spot" was coined by Addiego, Whipple et al. in 1981.[1] A discrete G-spot has not been confirmed anatomically, and an alternative view attributes the responsive area to the broader clitoral-urethral-vaginal complex.[1] The concept has nonetheless driven commercial interest and the development of G-spot amplification procedures.[1][4]

Procedure​

G-spot amplification has been described as filler injection into the bladder–vaginal septum of the anterior vaginal wall, approximately 2–3 cm inside the introitus, at a putative G-spot.[1][2] A 31-study systematic review found no reproducible location, size or nature for a distinct G-spot.[15]

Injectable agents​

AgentDescriptionDuration
Hyaluronic acid (HA) dermal fillerMost commonly used. Cross-linked HA provides temporary volume augmentation.About 9–12 months (expected reabsorption period of the product in one series)[5]
Collagen-based fillerEarlier formulations (human-derived collagen)3–4 months[1]
Autologous fat (microfat / MAFT)Harvested via liposuction; provides volume and possible regenerative effects via adipose-derived stem cells (ADSCs)Variable; no G-spot-specific duration estimate. In one additional patient outside Lai's 20-patient series, vaginal histology showed fat grafts 3 months after MAFT.[6] Menkes reported improved VHI and FSD scores through 18 months after labia-majora microfat and vaginal nanofat for GSM.[7]

Technique — HA injection​

  • Preprocedure safety. U.S. dermal-filler approvals cover specified facial and hand uses, not vaginal injection. Disclose the unapproved site and uncertain risks, assess active infection and filler or anesthetic allergy, and establish a response plan for vascular injury.[19]
  • Anesthesia. Local (topical or infiltrative).
  • Injection. Anterior-vaginal-wall filler placement has been described, but no validated G-spot target, HA volume or injection plane is established.[1][2] A separate posterior-wall augmentation series used 3–5 mL of cross-linked HA.[5]
  • Procedure time. Approximately 15–30 min as an outpatient procedure.

Technique — autologous fat injection​

  • Fat harvested from abdomen / thighs / flanks via liposuction; processed (washed, filtered, or centrifuged) into microfat or nanofat; injected into the vaginal wall. In one G-spot-specific case report, Herold et al. harvested trochanteric fat by water-assisted liposuction, catheterized the urethra, and injected 8 mL into the anterior vaginal submucosa. Reported increased stimulation resolved after 2 weeks, and standardized well-being and sexual-function questionnaires did not show improvement.[17]
  • In a separate retrospective vulvovaginal MAFT series (n = 20), Lai et al. injected the posterior vaginal wall, not the putative anterior-wall G-spot; mean volumes were 21.9 mL vaginally and 20.8 mL into the vulva and mons.[6]
  • More involved than HA injection; requires a donor-site procedure.

Proposed mechanism of action​

The theoretical rationale is that increasing the volume and turgor of anterior vaginal wall tissue at the G-spot area would:

  • Increase mechanical pressure on underlying nerve-rich tissue during intercourse.
  • Enhance sensitivity and arousal.
  • Facilitate vaginal orgasm.

For autologous fat, tissue regeneration through ADSCs has also been proposed. In Lai 2023, vaginal histology after fat grafting showed neocollagenesis, neoangiogenesis and increased estrogen-receptor expression.[6]

Evidence — extremely limited for G-spot amplification specifically​

The evidence base for G-spot amplification specifically is very limited. ACOG's statement covers laser assistance, rugation restoration and G-spot amplification together: "Scant information on the outcomes (risks and benefits) of laser assistance, rugation restoration, or G-spot amplification exists in the peer-reviewed literature, and the published data are mostly restricted to expert opinion, case reports, or small case series."[2]

Adjacent vaginal-augmentation evidence (NOT G-spot-specific)​

StudyAgentnFollow-upKey outcomes
Yi 2026[5]Cross-linked HA (posterior vaginal wall)4212 moAll FSFI domains improved; 81% satisfaction at 12 months; improved Peritron parameters; Level of evidence V
Lai 2023[6]Autologous fat (MAFT, vulvovaginal), retrospective206 moAuthors reported total FSFI 43.8 to 68.6 (p < 0.001), above the standard 36-point maximum; scoring requires clarification. Histology showed neocollagenesis and neoangiogenesis.[14]
Menkes 2021[7]Microfat (labia majora) and nanofat (vagina)5018 moVHI and FSD scores improved significantly at 1 and 3 months; data for 80% of patients appeared normalized at 6 months, and results remained stable at 18 months
Clarke 2026 pilot RCT (single-blind)[8]PRP (distal anterior vaginal wall) vs saline, premenopausal women without severe sexual dysfunction526 moMedian FSFI change at 6 weeks (primary outcome) 2.2 vs 0.3; at 6 months 1.6 vs 0.8 (p = 0.05); PGI-I improvement 69.2% vs 34.6% at 6 months (p = 0.01)
Bensmail 2025[9]Cross-linked HA (vulvovaginal atrophy, postmenopausal); 12-week placebo-controlled phase then open-label115 HA-exposed across both sequences52 weeks after injection for the initial HA group; 36 weeks after HA for placebo-first patientsAt 12 weeks, HA versus placebo improved the most-bothersome-symptom score by 0.58 points (95% CI 0.16–1.01) and FSFI by 3.81 points (95% CI 0.91–6.72).[16] Later improvements were from baseline without a placebo comparator.[9]

The Clarke 2026 anterior-vaginal-wall PRP pilot RCT is the closest available proxy. It showed a greater FSFI increase with PRP than with saline at 6 weeks, but the FSFI subscale differences did not reach statistical significance and the 6-month total FSFI difference had overlapping confidence intervals (p = 0.05).[8]

Duration of effect​

AgentTypical duration
HA fillersThe product in a posterior-wall augmentation series had an expected reabsorption period of about 9–12 months.[5]
Autologous fatThe cited series did not measure graft retention or G-spot-specific duration. In 50 women with GSM receiving labia-majora microfat plus vaginal nanofat, symptom scores remained improved at 18 months.[7]
Collagen3–4 mo[1]

Complications​

ACOG lists pain, bleeding, infection, scarring, adhesions, altered sensation, dyspareunia and reoperation as potential complications of cosmetic genital procedures.[2]

ComplicationNotes
PainInjection-site or donor-site pain may occur; sudden severe abdominal or vulvar pain warrants urgent assessment for vascular injury.[12][13]
BleedingSubmucosal hematoma is possible; its frequency after G-spot injection is unknown.[2]
InfectionPossible; frequency after G-spot injection is unknown.[2]
Scarring / adhesionsPossible; frequency after G-spot injection is unknown.[2]
Altered sensationHyper- or hyposensitivity reported
DyspareuniaPossible, especially with over-correction
Filler migration / granulomaTheoretical with HA; not specifically reported in vaginal G-spot use
Filler embolism / ischemiaFatal pulmonary embolism followed vaginal HA injection by an unlicensed practitioner; two further autopsy cases followed vaginal HA or combined collagen and HA/polylactic-acid fillers. Arterial occlusion with local necrosis followed vulvovaginal HA injection.[12][13][18]
Donor-site morbidityAutologous fat technique only
Fat embolismSevere pulmonary fat embolism was reported after combined vaginal-tightening and breast-augmentation fat grafting; simultaneous injection sites prevent certain attribution to the vaginal procedure.[20]
Need for reoperation / repeat injectionACOG lists reoperation as a possible harm. Retreatment rates and timing after G-spot injection are unknown; the 9–12-month figure is expected product reabsorption in a posterior-wall series.[2][5]

The small vaginal HA and fat-injection series reported no serious adverse events, but small samples and short follow-up limit detection of rare complications.[5][6][7]

Distinction — cosmetic G-spot amplification vs therapeutic vaginal augmentation​

The two indications differ:

Use caseStatusEvidence
G-spot amplification for sexual enhancement in healthy womenCosmetic; not medically indicated; lacks evidenceExpert opinion / case reports / small series only[1][2]
Vaginal HA / fat injection for genitourinary syndrome of menopause (GSM)Emerging therapeutic applicationBensmail 2025 (12-week placebo-controlled phase, then open-label to 52 weeks); Menkes 2021 microfat and nanofat to 18 months; Mantovani 2022 microfragmented fat (n = 12, 5 months)[9][7][10]

The GSM application has randomized data for HA and small observational series for fat.

Emerging techniques​

TechniqueDescriptionReference
Cannulated Intravaginal Injection Technique (CIVIT)Cannula-based HA delivery intended to distribute injections more evenly with fewer punctures. In a retrospective comparison of 44 symptomatic postmenopausal women, FSFI and vaginal health index scores were higher and genitourinary symptom scores lower at 6 weeks than with random needling; FSFI arousal did not differ.Leylek 2025[11]
Anterior-vaginal-wall PRPPilot single-blind RCT of a one-time injection; greater FSFI increase than saline at 6 weeks and more women reporting improvement at 6 months (PGI-I 69.2% vs 34.6%, p = 0.01)Clarke 2026[8]
Microfragmented adipose tissueMinimally processed adipose tissue injection for GSM; an uncontrolled 12-woman series reported improved symptom scores at 5 months. A published correction disclosed that one author was CEO of the studied device's manufacturer.[21]Mantovani 2022[10]

Key takeaways​

  • ACOG describes the evidence for G-spot amplification and related procedures as mostly restricted to expert opinion, case reports, or small case series.[2]
  • The anatomical existence of the G-spot as a discrete structure is disputed.[1]
  • ACOG 2020 and FIGO 2025. ACOG states that cosmetic genital procedures are not medically indicated.[2] FIGO states that it is ethically inappropriate to recommend, perform or refer patients for them in women without structural or functional abnormalities.[3]
  • The broader vaginal-augmentation literature (HA, fat and PRP for GSM and vulvovaginal atrophy) includes randomized data.
  • The HA product in a posterior-wall series was expected to resorb over about 9–12 months; clinical duration and retreatment need after G-spot injection have not been measured.[5] Discuss uncertain durability and the possible cost of repeat treatment.

Postoperative management​

  • Activity restriction. In Lai's posterior-wall MAFT series, patients were advised to avoid intercourse and strenuous exercise for at least 2 weeks.[6] A G-spot-specific restriction interval after HA injection or for tampon use is unestablished, and a 4-week restriction has not been shown to protect fat-graft survival.[2]
  • Wound care. Generally not required after HA injection; sitz baths / loose clothing if discomfort.
  • Donor-site care for autologous fat: compression, ice, monitor for hematoma.
  • Follow-up. New severe abdominal or vulvar pain, dyspnea, syncope, or necrotic skin change after injection warrants urgent assessment for embolic or ischemic injury.[12][13] An initial check at 2 weeks and functional or satisfaction assessments at 3 and 6 months can document symptoms and adverse events. Discuss uncertain durability and any retreatment according to the agent.

See Also​

References​

1. Puppo V, Gruenwald I. Does the G-spot exist? A review of the current literature. Int Urogynecol J. 2012;23(12):1665–1669. doi:10.1007/s00192-012-1831-y

2. Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. Elective female genital cosmetic surgery: ACOG Committee Opinion No. 795. Obstet Gynecol. 2020;135(1):e36–e42. doi:10.1097/AOG.0000000000003616

3. Capito L, Antsaklis A, Gupte S. FIGO Statement: cosmetic genital surgery. Int J Gynaecol Obstet. 2025;170(1):11–14. doi:10.1002/ijgo.70203

4. Wilkie G, Bartz D. Vaginal rejuvenation: a review of female genital cosmetic surgery. Obstet Gynecol Surv. 2018;73(5):287–292. doi:10.1097/OGX.0000000000000559

5. Yi KH, Kim JH, Rosellini I, et al. Hyaluronic acid fillers for vaginal augmentation: efficacy and safety. Aesthet Plast Surg. 2026;50(7):2626–2632. doi:10.1007/s00266-025-05587-0

6. Lai YW, Wu SH, Chou PR, et al. Autologous fat grafting in female genital area improves sexual function by increasing collagenesis, angiogenesis, and estrogen receptors. Aesthet Surg J. 2023;43(8):872–884. doi:10.1093/asj/sjad040

7. Menkes S, SidAhmed-Mezi M, Meningaud JP, et al. Microfat and nanofat grafting in genital rejuvenation. Aesthet Surg J. 2021;41(9):1060–1067. doi:10.1093/asj/sjaa118

8. Clarke B, Gaddam N, Garcia B, et al. Vaginal injection of platelet-rich plasma for sexual function: a randomized controlled trial. Obstet Gynecol. 2026;147(5):627–635. doi:10.1097/AOG.0000000000006256

9. Bensmail H, Marchand Lamiraud F, Martin C, et al. Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy and improve sexual function in postmenopausal women: a 52-week long-term follow-up. Maturitas. 2025;201:108687. doi:10.1016/j.maturitas.2025.108687

10. Mantovani M, Gennai A, Russo PR. A new approach to regenerative medicine in gynecology. Int J Gynaecol Obstet. 2022;157(3):536–543. doi:10.1002/ijgo.13906

11. Leylek O, Peker BH, Demircivi E, Peker H. Cannulated intravaginal injection technique (CIVIT) — a novel vaginal injection technique. Sci Rep. 2025;15(1):7651. doi:10.1038/s41598-025-91069-x

12. Kong J, Yang T, Yang X, Zhang F, Liao X, Li D. "Death from pulmonary embolism caused by vaginal injection of hyaluronic acid: a case report and a literature review." Aesthetic Plast Surg. 2023;47(4):1535–1541. doi:10.1007/s00266-023-03265-7

13. Lin P, Zhou G, Li G, et al. "Superselective internal pudendal artery thrombolytic therapy combined with concentrated growth factor for hyaluronic acid embolization after vulvovaginal rejuvenation: a case report and review of literature." Aesthetic Plast Surg. 2026;50(7):2814–2822. doi:10.1007/s00266-025-05184-1

14. Sánchez-Sánchez B, Navarro-Brazález B, Arranz-Martín B, Sánchez-Méndez Ó, de la Rosa-Díaz I, Torres-Lacomba M. "The Female Sexual Function Index: transculturally adaptation and psychometric validation in Spanish women." Int J Environ Res Public Health. 2020;17(3):994. doi:10.3390/ijerph17030994

15. Vieira-Baptista P, Lima-Silva J, Preti M, Xavier J, Vendeira P, Stockdale CK. "G-spot: fact or fiction? A systematic review." Sex Med. 2021;9(5):100435. doi:10.1016/j.esxm.2021.100435

16. Marchand Lamiraud F, Bensmail H, Martin C, et al. "Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy in postmenopausal women: a 12-week randomised, placebo-controlled, multicentric study." Maturitas. 2025;197:108264. doi:10.1016/j.maturitas.2025.108264

17. Herold C, Motamedi M, Hartmann U, Allert S. "G-spot augmentation with autologous fat transplantation." J Turk Ger Gynecol Assoc. 2015;16(3):187–188. doi:10.5152/jtgga.2015.15027

18. Lim S, Kim S, Choi SG, Park S. "Fatal non-thrombotic pulmonary embolism after vaginal filler injection: a report of two autopsy cases and literature review." Korean J Leg Med. 2025;49(1):7–15. doi:10.7580/kjlm.2025.49.1.7

19. U.S. Food and Drug Administration. "Dermal Fillers (Soft Tissue Fillers)." FDA. Accessed October 8, 2026.

20. Wang C, Wang X, Huang J, Yu N, Long X. "Severe fat embolism after autologous fat grafting in vaginal tightening and breast augmentation surgery." J Int Med Res. 2020;48(8):300060520949109. doi:10.1177/0300060520949109

21. "Correction to A new approach to regenerative medicine in gynecology." Int J Gynaecol Obstet. 2024;165(2):844. doi:10.1002/ijgo.15471